Phase 2 Study of Zanubrutinib in Patients with Relapsed/Refractory B-Cell Malignancies Intolerant to Ibrutinib/Acalabrutinib

MLA

Syed F. Zafar, et al. “Phase 2 Study of Zanubrutinib in Patients with Relapsed/Refractory B-Cell Malignancies Intolerant to Ibrutinib/Acalabrutinib.” Blood, vol. 136, Nov. 2020, pp. 51–52. EBSCOhost, https://doi.org/10.1182/blood-2020-134621.

APA

Syed F. Zafar, Benjamin Bruce Freeman, Habte A. Yimer, John M. Burke, Mazyar Shadman, Dih-Yih Chen, Jennifer L. Cultrera, Jamal Misleh, Moshe Yair Levy, Ian W. Flinn, Xiaoping Zhang, Jane Huang, Sunhee Ro, Jeff P. Sharman, & Aileen Cohen. (2020). Phase 2 Study of Zanubrutinib in Patients with Relapsed/Refractory B-Cell Malignancies Intolerant to Ibrutinib/Acalabrutinib. Blood, 136, 51–52. https://doi.org/10.1182/blood-2020-134621

Chicago

Syed F. Zafar, Benjamin Bruce Freeman, Habte A. Yimer, John M. Burke, Mazyar Shadman, Dih-Yih Chen, Jennifer L. Cultrera, et al. 2020. “Phase 2 Study of Zanubrutinib in Patients with Relapsed/Refractory B-Cell Malignancies Intolerant to Ibrutinib/Acalabrutinib.” Blood 136 (November): 51–52. doi:10.1182/blood-2020-134621.